This HTML5 document contains 91 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00703/identifier/national-drug-code-directory/
n9http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00703/identifier/chemspider/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00703/identifier/wikipedia/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00703/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00703/identifier/kegg-compound/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00703/identifier/bindingdb/
n14http://www.rxlist.com/cgi/generic2/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00703/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00703/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00703/identifier/kegg-drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00703/identifier/drugbank/
n24http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00703
rdf:type
n3:Drug
n3:description
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. [PubChem]
n3:dosage
n23:271B4975-363D-11E5-9242-09173F13E4C5 n23:271B4974-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Iyer GR, Bellantone RA, Taft DR: In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics. J Pharmacokinet Biopharm. 1999 Feb;27(1):45-66. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10533697 # Shirato S, Kagaya F, Suzuki Y, Joukou S: Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol. 1997 Apr;115(4):550-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9109770 # Skorobohach BJ, Ward DA, Hendrix DV: Effects of oral administration of methazolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs. Am J Vet Res. 2003 Feb;64(2):183-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12602587
n3:group
approved
n3:halfLife
14 hours
n3:indication
For treatment of chronic open-angle glaucoma and acute angle-closure glaucoma
n3:manufacturer
n5:271B496B-363D-11E5-9242-09173F13E4C5 n5:271B496C-363D-11E5-9242-09173F13E4C5 n5:271B496D-363D-11E5-9242-09173F13E4C5 n5:271B496E-363D-11E5-9242-09173F13E4C5 n5:271B496A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00703 n27:DB00703
dcterms:title
Methazolamide
adms:identifier
n11:3958 n12:DB00703 n15:10881 n16:D00655 n17:0781-1072-01 n18:C07764 n19:46506393 n20:PA450413 n22:4100 n28:Methazolamide
n3:mechanismOfAction
Methazolamide is a potent inhibitor of carbonic anhydrase. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.
n3:packager
n5:271B4960-363D-11E5-9242-09173F13E4C5 n5:271B4969-363D-11E5-9242-09173F13E4C5 n5:271B4968-363D-11E5-9242-09173F13E4C5 n5:271B4966-363D-11E5-9242-09173F13E4C5 n5:271B4967-363D-11E5-9242-09173F13E4C5 n5:271B4964-363D-11E5-9242-09173F13E4C5 n5:271B4965-363D-11E5-9242-09173F13E4C5 n5:271B4962-363D-11E5-9242-09173F13E4C5 n5:271B4963-363D-11E5-9242-09173F13E4C5 n5:271B4961-363D-11E5-9242-09173F13E4C5 n5:271B495E-363D-11E5-9242-09173F13E4C5 n5:271B495F-363D-11E5-9242-09173F13E4C5
n3:synonym
Methazolamid Méthazolamide SID26747005 Metazolamida Methazolamidum
n3:toxicity
Electrolyte imbalance, development of an acidotic state, and central nervous system effects might be expected to occur in the case of an overdose.
n3:volumeOfDistribution
* 17 to 23 L
n8:hasAHFSCode
n9:52-10-00
n3:foodInteraction
Take with food, more than 6 hours before bedtime increase liquid intake.
n3:proteinBinding
55%
foaf:page
n14:methaz.htm n21:methazolamide.html
n3:IUPAC-Name
n4:271B497A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4980-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B497F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B497C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B497D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B497E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4978-363D-11E5-9242-09173F13E4C5 n4:271B4990-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4979-363D-11E5-9242-09173F13E4C5 n4:271B4976-363D-11E5-9242-09173F13E4C5 n4:271B4992-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4977-363D-11E5-9242-09173F13E4C5 n4:271B4993-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4994-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n24:S01EC05
n3:H-Bond-Acceptor-Count
n4:271B4986-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4987-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4981-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4982-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4984-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4983-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4985-363D-11E5-9242-09173F13E4C5
n3:absorption
Methazolamide is well absorbed from the gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
554-57-4
n3:containedIn
n26:271B4972-363D-11E5-9242-09173F13E4C5 n26:271B4973-363D-11E5-9242-09173F13E4C5 n26:271B4970-363D-11E5-9242-09173F13E4C5 n26:271B4971-363D-11E5-9242-09173F13E4C5 n26:271B496F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B498C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B498E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B498F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4991-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B498B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B498A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B498D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B497B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4988-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4989-363D-11E5-9242-09173F13E4C5